Skandinaviska Enskilda Banken AB publ Has $4.07 Million Position in Biogen Inc. $BIIB

Skandinaviska Enskilda Banken AB publ decreased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 56.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,083 shares of the biotechnology company’s stock after selling 38,148 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Biogen were worth $4,073,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Biogen by 1.5% during the second quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock worth $2,171,533,000 after acquiring an additional 257,812 shares during the last quarter. State Street Corp increased its position in Biogen by 1.0% in the second quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after purchasing an additional 71,897 shares during the period. Geode Capital Management LLC raised its holdings in Biogen by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company’s stock worth $490,089,000 after purchasing an additional 71,286 shares during the last quarter. Invesco Ltd. raised its holdings in Biogen by 2.4% during the 2nd quarter. Invesco Ltd. now owns 2,320,126 shares of the biotechnology company’s stock worth $291,385,000 after purchasing an additional 55,119 shares during the last quarter. Finally, Norges Bank acquired a new position in Biogen during the 2nd quarter valued at about $284,358,000. 87.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Wall Street Zen cut shares of Biogen from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. HC Wainwright raised their price objective on shares of Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a research note on Monday, February 9th. TD Cowen lifted their target price on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Finally, Stifel Nicolaus raised their price target on Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Twelve research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $205.04.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Biogen Trading Down 0.0%

Shares of NASDAQ BIIB opened at $192.03 on Friday. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The stock has a market cap of $28.18 billion, a price-to-earnings ratio of 21.80, a P/E/G ratio of 1.52 and a beta of 0.16. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company’s fifty day moving average is $180.02 and its 200-day moving average is $161.10.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: BIIB091 MS trial reaches completion — Phase 2 readout setup provides a near-term pipeline catalyst that could materially affect investor sentiment if results are favorable. Biogen’s BIIB091 MS Trial Reaches Completion
• Positive Sentiment: New Board chair Maria C. Freire appointed — her experience in biomedical research, drug development and public–private partnerships could refocus partnerships and capital allocation, which investors may view as constructive for strategy and M&A/partnering optionality. New Biogen Chair Freire May Recast Partnerships And Capital Priorities
• Positive Sentiment: Analyst / media coverage highlights improved valuation and strong recent performance — articles noting Biogen as a value / turnaround candidate and highlighting recent gains can attract investors hunting discounted quality names. This supports momentum in the stock. Assessing Biogen (BIIB) Valuation
• Positive Sentiment: Broader ALS therapeutics market growth — a market-research report projects strong CAGR for ALS therapeutics, which is relevant because Biogen has neuro/ALS programs (supporting longer-term revenue upside if clinical progress continues). Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share
• Neutral Sentiment: Macro/guidance context and value-stock debate — a piece on “value stocks walking a fine line” highlights valuation risks vs. margin of safety; useful context but not BIIB-specific catalyst. 3 Value Stocks Walking a Fine Line
• Neutral Sentiment: Short-interest data appears noisy/invalid — reported short-interest entries show zero/NaN values and thus offer no reliable signal about positioning or squeeze risk. (Treat with caution.)
• Negative Sentiment: New Alzheimer’s startup Korsana raises $175M — fresh venture capital backing for an Alzheimer’s program (originating at Paragon) increases competition in the amyloid/Alzheimer’s R&D landscape; could pressure long-term franchise assumptions depending on Korsana’s program profile and trial outcomes. An Alzheimer’s startup emerges with $175M in venture backing

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.